VA
MAZE

VR Adviser’s Maze Therapeutics MAZE Stock Holding History

VR Adviser’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.8M Buy
1,602,034
+53,465
+3% +$2.36M 1.78% 15
2025
Q4 		$64.2M Buy
1,548,569
+317,800
+26% +$10.9M 3.17% 11
2025
Q3 		$31.9M Buy
+1,230,769
New +$20.8M 1.8% 18

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

VR Adviser's MAZE Position: Q1 2026 in Review

VR Adviser increased its Maze Therapeutics (MAZE) stake by 3.5% in Q1 2026, buying an estimated $2.36M and bringing the position to 1,602,034 shares worth $47.8M. The position accounts for 1.78% of the portfolio, ranked #15.

VR Adviser first reported a position in MAZE in Q3 2025 and has held it in 3 quarters since. The position peaked at $64.2M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • VR Adviser held 1,602,034 shares of Maze Therapeutics worth $47.8M as of Q1 2026.
  • VR Adviser bought 53,465 Maze Therapeutics shares in Q1 2026, an estimated $2.36M.
  • Maze Therapeutics made up 1.78% of VR Adviser's portfolio in Q1 2026, its #15 holding.
  • VR Adviser first reported a position in Maze Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • VR Adviser's Maze Therapeutics position peaked at $64.2M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.